Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2018-06-21
Target enrollment:
Participant gender:
Summary
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in
Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently
responsive to topical beta-blocker or prostaglandin analogues.